Personalized Cannabinoid Formulations via AI-driven Genetic Analysis
Legal Citation
Summary of the Inventive Concept
A next-generation system for tailored cannabinoid formulations using machine learning, genetic analysis, and real-time optimization to revolutionize individualized medicine.
Background and Problem Solved
The original patent disclosed cannabinoid formulations aligned with an individual's genotype based on a defined list of polymorphisms. However, this approach has limitations in terms of scalability, accuracy, and adaptability. The new inventive concept addresses these limitations by introducing AI-driven genetic analysis, real-time optimization, and personalized dosing, enabling a more precise and effective approach to cannabinoid therapy.
Detailed Description of the Inventive Concept
The system comprises a genetic analysis module, a formulation optimization module, and a manufacturing or dosing module. The genetic analysis module receives genomic data from a subject and generates a personalized cannabinoid profile. The formulation optimization module uses machine learning to optimize the cannabinoid ratios and terpene profiles based on the personalized profile. The manufacturing or dosing module produces or dispenses the optimized formulation in real-time. This integrated system enables personalized cannabinoid formulations that can adapt to an individual's unique genetic profile and environmental factors.
Novelty and Inventive Step
The new claims introduce a paradigm shift by incorporating AI-driven genetic analysis, machine learning, and real-time optimization to create personalized cannabinoid formulations. This approach is novel and non-obvious compared to the original patent, which relied on predefined polymorphisms and manual formulation optimization.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the machine learning models, genetic analysis tools, and manufacturing or dosing methods. For example, the system could be integrated with wearable devices, mobile applications, or electronic health records to enhance user experience and data collection.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the personalized medicine and cannabis industries. Target markets may include pharmaceutical companies, dispensaries, and healthcare providers seeking to offer tailored cannabinoid therapies to patients. The system's adaptability and real-time optimization capabilities make it an attractive solution for addressing the complexities of individualized medicine.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically personalized medicine and cannabinoid formulation design, involving expertise in genomics, machine learning, pharmacogenomics, and pharmaceutical composition optimization
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in biotechnology, pharmacology, or biomedical engineering, possessing knowledge of genetic analysis, machine learning techniques, cannabinoid pharmacology, and personalized medicine approaches
Obviousness Rationale
The PTD represents a predictable technological progression from the source patent by applying established machine learning and genetic analysis techniques to the existing framework of personalized cannabinoid formulations. A PHOSITA would recognize that integrating AI-driven optimization with genetic profiling is a natural extension of the source patent's foundational approach of tailoring cannabinoid compositions to individual genetic characteristics. The technical implementation involves well-known computational methods and established personalized medicine paradigms that would be readily apparent to a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,530 |
|---|---|
| Title | Cannabinoid formulations |
| Assignee(s) | Endocanna Health, Inc. |